
QIAGEN N.V. QGEN
Annual report 2025
added 04-04-2026
QIAGEN N.V. Cost of Revenue 2011-2026 | QGEN
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue QIAGEN N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 801 M | 638 M | 521 M | 501 M | 495 M | 493 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 801 M | 493 M | 575 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
2.91 B | $ 115.48 | 0.82 % | $ 35.1 B | ||
|
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
144 M | $ 16.2 | -0.61 % | $ 175 M | ||
|
Aspira Women's Health
AWH
|
3.3 M | - | -6.19 % | $ 10.5 M | ||
|
Co-Diagnostics
CODX
|
222 K | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Castle Biosciences
CSTL
|
60.2 M | $ 24.84 | -0.84 % | $ 690 M | ||
|
DarioHealth Corp.
DRIO
|
9.69 M | $ 8.4 | 3.7 % | $ 33.5 M | ||
|
BioNano Genomics
BNGO
|
15.3 M | $ 1.2 | 0.84 % | $ 6.53 M | ||
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M | ||
|
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | ||
|
DexCom
DXCM
|
1.86 B | $ 62.22 | -0.24 % | $ 24.3 B | ||
|
Fulgent Genetics
FLGT
|
176 M | $ 16.82 | 2.31 % | $ 509 M | ||
|
Biomerica
BMRA
|
4.81 M | $ 2.17 | -0.91 % | $ 4.98 M | ||
|
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | ||
|
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | ||
|
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | ||
|
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 198.02 | 0.17 % | $ 22 B | ||
|
Guardant Health
GH
|
349 M | $ 93.83 | 2.94 % | $ 11.8 B | ||
|
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | ||
|
Lantheus Holdings
LNTH
|
600 M | $ 76.1 | 0.53 % | $ 5.14 B | ||
|
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | ||
|
Interpace Biosciences
IDXG
|
14.6 M | $ 1.96 | 5.82 % | $ 8.67 M | ||
|
ICON Public Limited Company
ICLR
|
3.97 B | $ 114.19 | 2.49 % | $ 9.42 B | ||
|
IDEXX Laboratories
IDXX
|
1.64 B | $ 569.55 | 0.87 % | $ 45.8 B | ||
|
Neogen Corporation
NEOG
|
473 M | $ 9.41 | 0.21 % | $ 2.04 B | ||
|
Illumina
ILMN
|
1.51 B | $ 127.38 | 0.59 % | $ 20.3 B | ||
|
IQVIA Holdings
IQV
|
10.9 B | $ 173.26 | 0.5 % | $ 29.8 B | ||
|
Pacific Biosciences of California
PACB
|
114 M | $ 1.34 | -0.74 % | $ 402 M | ||
|
Koninklijke Philips N.V.
PHG
|
9.99 B | $ 27.11 | -0.66 % | $ 20 B | ||
|
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K | ||
|
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 273.72 | 0.36 % | $ 22.8 B | ||
|
Myriad Genetics
MYGN
|
248 M | $ 4.75 | 3.49 % | $ 440 M | ||
|
Sotera Health Company
SHC
|
518 M | $ 14.96 | 0.61 % | $ 4.25 B | ||
|
NeoGenomics
NEO
|
413 M | $ 8.0 | 3.23 % | $ 1.02 B |